Evidence map›Paper›PMID 38780883›Full record

ArticleAngiogenesis2024

Human atherosclerotic plaque transcriptomics reveals endothelial beta-2 spectrin as a potential regulator a leaky plaque microvasculature phenotype.

Timo Rademakers, Marco Manca, Han Jin, Tanguy Orban, Ljubica Matic Perisic, Hubertus J M Frissen, Frank Rühle, Petra Hautvast, Jos van Rijssel, Kim van Kuijk and 12 more

Abstract read
In one paragraph

Article in Angiogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Endothelial βII Spectrin Deletion Exacerbates Inflammation and Impairs Tissue Regeneration in Ischemic-Diabetic Skin Wound Healing.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Timo RademakersDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Marco MancaDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Han JinDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Tanguy OrbanLaboratory of Protein Signaling and Interactions, GIGA, Liège Université, Liège, Belgium.
Ljubica Matic PerisicDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden.
Hubertus J M FrissenDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Frank RühleGenetic Epidemiology, Institute of Human Genetics, University of Münster, Münster, Germany.
Petra HautvastDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Jos van RijsselDepartment of Plasma Proteins, Laboratory for Molecular Cell Biology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
Kim van KuijkDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Barend M E MeesDepartment of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Carine J Peutz-KootstraDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Sylvia HeenemanDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Mat J A P DaemenDepartment of Pathology, Academic Medical Center (AMC), Amsterdam, The Netherlands.
Gerard PasterkampLaboratory of Clinical Chemistry and Haematology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
Monika StollGenetic Epidemiology, Institute of Human Genetics, University of Münster, Münster, Germany.
Marc A M J van ZandvoortDepartment of Molecular Cell Biology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
Ulf HedinDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden.
Franck DequiedtLaboratory of Protein Signaling and Interactions, GIGA, Liège Université, Liège, Belgium.
Jaap D van BuulDepartment of Plasma Proteins, Laboratory for Molecular Cell Biology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
Judith C SluimerDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands.
Erik A L BiessenDepartment of Pathology, Experimental Vascular Pathology Group, Maastricht University, PO box 5800, 6202 AZ, Maastricht, The Netherlands. erik.biessen@mumc.nl.

Funding

CARIM "Plaque neoangiogenesis"Centre for translational Molecular Medicine (CTMM) 01C-102
6 · The paper itself

Abstract

The presence of atherosclerotic plaque vessels is a critical factor in plaque destabilization. This may be attributable to the leaky phenotype of these microvessels, although direct proof for this notion is lacking. In this study, we investigated molecular and cellular patterns of stable and hemorrhaged human plaque to identify novel drivers of intraplaque vessel dysfunction. From transcriptome data of a human atherosclerotic lesion cohort, we reconstructed a co-expression network, identifying a gene module strongly and selectively correlated with both plaque microvascular density and inflammation. Spectrin Beta Non-Erythrocytic 1 (sptbn1) was identified as one of the central hubs of this module (along with zeb1 and dock1) and was selected for further study based on its predominant endothelial expression. Silencing of sptbn1 enhanced leukocyte transmigration and vascular permeability in vitro, characterized by an increased number of focal adhesions and reduced junctional VE-cadherin. In vivo, sptbn1 knockdown in zebrafish impaired the development of the caudal vein plexus. Mechanistically, increased substrate stiffness was associated with sptbn1 downregulation in endothelial cells in vitro and in human vessels. Plaque SPTBN1 mRNA and protein expression were found to correlate with an enhanced presence of intraplaque hemorrhage and future cardiovascular disease (CVD) events during follow-up. In conclusion, we identify SPTBN1 as a central hub gene in a gene program correlating with plaque vascularisation. SPTBN1 was regulated by substrate stiffness in vitro while silencing blocked vascular development in vivo, and compromised barrier function in vitro. Together, SPTBN1 is identified as a new potential regulator of the leaky phenotype of atherosclerotic plaque microvessels.

Indexed as

MicrovesselsPlaque, AtheroscleroticSpectrinZebrafishAnimalsCapillary PermeabilityHumansHuman Umbilical Vein Endothelial CellsPhenotypeTranscriptomeSpectrinSPTBN1 protein, humanAtherosclerosisLeaky vesselsPlaque microvesselsStiffnessVascular biology

Identifiers

PMID38780883
PMCPMC11303431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.